United States securities and exchange commission logo

                           August 12, 2020

       Robert J. Gould, Ph.D.
       President and Chief Executive Officer
       Fulcrum Therapeutics, Inc.
       26 Landsdowne Street
       Cambridge, Massachusetts 02139

                                                        Re: Fulcrum
Therapeutics, Inc.
Statement on Form S-3
                                                            Filed August 11,
                                                            File No. 333-244136

       Dear Dr. Gould:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Chris
Edwards at (202) 551-6761 with any questions.


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Lia Der Marderosian,